Liberate Medical

Liberate Medical

Liberate Medical is a medical device company focused on pulmonary care founded in 2013.

Liberate Medical develops medical devices for patients with pulmonary indications to improve quality of life and reduce cost of care that is headquartered in Crestwood Kentucky and was founded in 2013 by Angus Mclachlan, Cedric Francois, Larry Horn, Pascal Deschatelets, and Renato La Rocca.

Liberate Medical develops medical devices for patients with pulmonary indications to improve quality of life and reduce cost of care. The company developed the VentFree muscle stimulator, an electrotherapy device that stimulates the abdominal wall muscles in a synchronized manner with mechanical ventilation. VentFree is designed to reduce the time for weaning patients off mechanical ventilation. The VentFree muscle stimulator received Breakthrough Device Designation from the FDA in January, 2019. The device is reported to have demonstrated feasibility to treat mechanically-ventilated critical care patients.

The VentFree Respiratory Muscle Stimulator received FDA Emergency Use Authorization (EUA) to reduce disuse atrophy of abdominal wall muscles to potentially reduce the number of days adult patients require mechanical ventilation, including patients with COVID-19 respiratory disease caused by SARS-Cov-2. Two pilot randomized controlled trials in Europe and Australia found that compared with placebo stimulation, VentFree may reduce ventilation duration and ICU stay duration. Alira Health, a healthcare and life sciences advisory firm, supported Liberate Medical in their FDA EUA application.

In October 2019 Liberate Medical announced gaining approval to sell its products in Europe from the European Union Regulatory body. Liberate medical plans on selling their VentFree device to European distributors instead of selling directly to hospitals.

Funding

XLerateHealth

Liberate Medical is a company that participated in the XLerateHealth 08/01/13 cohort and raised an estimated $2,310,000. In May 2019 Liberate Medical closed a $1.35 million fundraising round.

Angel round

On December 21, 2016 Liberate Medical announced raising $650,000 in angel funding from undisclosed investors.

Grant

On January 1, 2017 Liberate Medical received a $250,000 grant from an undisclosed source.

Timeline

May 4, 2020

Liberate Medical received Federal Drug Administration (FDA) emergency use authorization for VentFree™ Respiratory Muscle Stimulator during the COVID-19 pandemic

October 29, 2019

Received CE mark, certification mark from a European Union regulatory body that allows device makers to sell their products

July 24, 2019

Abdominal functional electrical stimulation to assist ventilator weaning in critical illness: a double-blinded, randomised, sham-controlled pilot study

Pilot study demonstrated the feasibility of using abdominal FES with critically ill mechanically ventilated patients. ICU and ventilation duration were shorter although study was not adequately powered for statistical conclusion.

January 1, 2017

Liberate Medical raises a $250,000 grant.

December 21, 2016

Liberate Medical raises a $750,000 angel round.

September 15, 2016

Liberate Medical raises a $750,000 grant from National Science Foundation.

October 1, 2014

Liberate Medical raises a $150,000 grant.

June 1, 2014

Liberate Medical raises a $250,000 grant from National Science Foundation.

June 29, 2013

Founded, spun off from Apellis Pharmaceuticals

Funding rounds

Funding round
Description
Funding type
Funding round amount (USD)
Funding round date
Investment
5 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Angus McLachlan

CEO, Co-Founder

Cedric Francois

Co-Founder

Larry Horn

Co-Founder

Pascal Deschatelets

Co-Founder

Renato La Rocca

Co-Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Page 1 of 2
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.